SCHEMBL10160183

SCHEMBL10160183

O=C(NCCc1cccc([N+](=O)[O-])c1)c1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.85
HPGD P15428 4/20 0.85
ALDH1A1 P00352 3/20 0.85
L3MBTL1 Q9Y468 3/20 0.73
RAB9A P51151 5/20 0.73
NPC1 O15118 4/20 0.73
TAAR1 Q96RJ0 1/20 0.73
CXCR3 P49682 1/20 0.64
PKM P14618 1/20 0.60
THRB P10828 1/20 0.57
ALOX12 P18054 1/20 0.57
LMNA P02545 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
HDAC3 O15379 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC10 Q969S8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156900 0.86 ALDH1A1 (0.67) SMN1; SMN2HPGDALDH1A1RAB9ANPC1
SCHEMBL2828273 0.86 ALDH1A1 (0.67) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
SCHEMBL2828269 0.86 ALDH1A1 (0.67) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
SCHEMBL6962971 0.85 SMN1; SMN2 (0.89) SMN1; SMN2HPGDALDH1A1RAB9ANPC1
SCHEMBL11024162 0.85 RAB9A (1.00) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
SCHEMBL4067332 0.83 PKM (0.82) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
Dinitrophenylene SCHEMBL27269874 0.83 ALDH1A1 (0.67) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
SCHEMBL6967304 0.83 ALDH1A1 (0.93) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
SCHEMBL27723289 0.83 ALDH1A1 (0.83) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A
Nitric Acid SCHEMBL18329349 0.83 RAB9A (0.76) SMN1; SMN2HPGDALDH1A1L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093266-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-10 US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
CN-1989138-A 2-Substituted-4-heteroaryl-pyrimidines useful in the treatment of proliferative diseases CYCLACEL LTD (GB) 2007-06-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041645-A1 RHO KINASE INHIBITORS CIT, ROCK1, RHOT2 SMN1; SMN2 2901/4885HPGD 419/4885ALDH1A1 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.